Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, CA; Infectious Diseases Division, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Am J Infect Control. 2018 Dec;46(12):1370-1374. doi: 10.1016/j.ajic.2018.04.213. Epub 2018 May 18.
Antimicrobial use is one of the largest modifiable risk factors for development of Clostridium difficile infection (CDI). We sought to determine if a recent diagnosis of CDI affected the appropriateness of subsequent antimicrobial prescribing.
This study is a retrospective electronic chart review of the Greater Los Angeles Veterans Administration. Medication administration records were reviewed for all patients with new CDI from 2015-2016 to determine the appropriateness (drug choice, duration, and dosage) of all non-CDI antimicrobials prescribed within 90 days pre- and post-initial CDI (iCDI) positive testing.
Of the 210 patients diagnosed with new-onset iCDI, 140 met inclusion criteria. Of antimicrobial courses prescribed, 40.6% of pre-iCDI were inappropriate compared with 43.1% of post-iCDI, demonstrating no difference in prescribing habits (P = .717). Thirty-three patients developed recurrent CDI (rCDI). After adjustment for other known risk factors, inappropriate antimicrobial use was associated with a significant increased risk of recurrence compared with appropriate use alone (odds ratio [OR], 6.19; 95% confidence interval [CI], 1.45-26.42). Antimicrobial use in general was associated with increased recurrence compared with no antimicrobial use post-iCDI (OR, 2.6; 95% CI, 1.16-5.84); however, after adjustment, it was no longer significant (OR, 2.13; 95% CI, 0.90-5.04).
The appropriateness of antimicrobial prescribing was not affected by the diagnosis of recent CDI. Inappropriate antimicrobial use after iCDI was associated with higher risk of rCDI.
抗菌药物的使用是导致艰难梭菌感染(CDI)的最大可改变风险因素之一。我们旨在确定近期 CDI 诊断是否会影响随后抗菌药物的使用是否恰当。
本研究是对大洛杉矶退伍军人事务部的回顾性电子病历审查。对 2015-2016 年所有新发 CDI 患者的药物管理记录进行了审查,以确定在初始 CDI(iCDI)阳性检测前 90 天内开具的所有非 CDI 抗菌药物的适当性(药物选择、持续时间和剂量)。
在 210 例确诊为新发 iCDI 的患者中,有 140 例符合纳入标准。在开具的抗菌药物疗程中,iCDI 前的不合理处方占 40.6%,而 iCDI 后的不合理处方占 43.1%,表明用药习惯没有差异(P=0.717)。33 例患者发生复发性 CDI(rCDI)。在调整其他已知危险因素后,与单独合理用药相比,不合理抗菌药物使用与 rCDI 显著增加的风险相关(比值比[OR],6.19;95%置信区间[CI],1.45-26.42)。与 iCDI 后未使用抗菌药物相比,一般抗菌药物使用与复发风险增加相关(OR,2.6;95%CI,1.16-5.84);然而,调整后,这不再具有统计学意义(OR,2.13;95%CI,0.90-5.04)。
近期 CDI 诊断不会影响抗菌药物处方的适当性。iCDI 后不合理使用抗菌药物与 rCDI 的风险增加相关。